REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
Complications and death from coronavirus disease 2019 (Covid-19) may be related to high viral loads. Two fully human, neutralizing monoclonal antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein were used. Key endpoints included the time-weighted average change in viral load from baseline (day 1) through day 7. Safety outcomes were similar in the combined REGN-COV2 dose groups and the placebo group.
